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BACKGROUND: There is great interest in widening the use of high-
sensitivity cardiac troponins for population cardiovascular disease (CVD) 
and heart failure screening. However, it is not clear whether cardiac 
troponin T (cTnT) and troponin I (cTnI) are equivalent measures of risk 
in this setting. We aimed to compare and contrast (1) the association 
of cTnT and cTnI with CVD and non-CVD outcomes, and (2) their 
determinants in a genome-wide association study.
METHODS: High-sensitivity cTnT and cTnI were measured in serum 
from 19 501 individuals in Generation Scotland Scottish Family Health 
Study. Median follow-up was 7.8 years (quartile 1 to quartile 3, 7.1–
9.2). Associations of each troponin with a composite CVD outcome 
(1177 events), CVD death (n=266), non-CVD death (n=374), and heart 
failure (n=216) were determined by using Cox models. A genome-wide 
association study was conducted using a standard approach developed 
for the cohort.
RESULTS: Both cTnI and cTnT were strongly associated with CVD risk in 
unadjusted models. After adjusting for classical risk factors, the hazard 
ratio for a 1 SD increase in log transformed troponin was 1.24 (95% CI, 
1.17–1.32) and 1.11 (1.04–1.19) for cTnI and cTnT, respectively; ratio of 
hazard ratios 1.12 (1.04–1.21). cTnI, but not cTnT, was associated with 
myocardial infarction and coronary heart disease. Both cTnI and cTnT had 
strong associations with CVD death and heart failure. By contrast, cTnT, 
but not cTnI, was associated with non-CVD death; ratio of hazard ratios 
0.77 (0.67–0.88). We identified 5 loci (53 individual single-nucleotide 
polymorphisms) that had genome-wide significant associations with cTnI, 
and a different set of 4 loci (4 single-nucleotide polymorphisms) for cTnT.
CONCLUSIONS: The upstream genetic causes of low-grade elevations 
in cTnI and cTnT appear distinct, and their associations with outcomes 
also differ. Elevations in cTnI are more strongly associated with some 
CVD outcomes, whereas cTnT is more strongly associated with the risk of 
non-CVD death. These findings help inform the selection of an optimal 
troponin assay for future clinical care and research in this setting.
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The 99th centile of high-sensitivity cardiac troponin 
T (cTnT) and troponin I (cTnI), derived from a normal 
reference population, is used to detect myocardial ne-
crosis as part of a diagnosis of myocardial infarction.1,2 
However, low-grade elevations in troponin in the gen-
eral population, well below the diagnostic threshold, 
are also associated with future cardiovascular disease 
(CVD) events and may have a role in screening the gen-
eral population for CVD risk.3,4
In existing cohort studies, high-sensitivity cTnI or 
cTnT are frequently measured individually without an 
evidence-based decision as to which biomarker might 
be preferable to achieve a specific aim. This is reflected 
in a recent study-level meta-analysis where 13 studies 
measured cTnI and 7 studies measured cTnT, although 
none measured both.4 One study has compared the 
performance of different cTnI assays in the general 
population.5 Our own recent data highlight differential 
cross-sectional associations of cTnI and cTnT with clas-
sical CVD risk factors, and their relatively weak associa-
tion with each other in a general population.6 Therefore, 
there is a need for a systematic approach to compare 
high-sensitivity cTnI and cTnT and their associations with 
a range of CVD and non-CVD health outcomes. Such a 
study has the potential to prioritize which of these as-
says should be used to improve CVD risk prediction, and 
for future measurement in established biobanks.
As a separate issue, the causal upstream determi-
nants of troponin elevation in the general population 
are not clear. The use of genetic variants to investigate 
potential causal pathways is now well established.7 A 
genome-wide association study (GWAS) of 11 544 indi-
viduals has been reported for cTnT,8 but there are cur-
rently limited data reported on genetic determinants 
of either troponin. Contrasting the upstream genetic 
determinants of low-grade elevations in cTnI and cTnT 
would allow further mechanistic insight into potential 
differences in their causal determinants.
Using clinical high-sensitivity assays, we measured 
both cTnT and cTnI in 19 501 individuals in the Genera-
tion Scotland Scottish Family Health Study (GS:SFHS). 
We aimed to contrast the associations of cTnI and cTnT 
with risk of CVD and non-CVD health outcomes, and to 
conduct a GWAS for both of the biomarkers to investi-
gate differences in both the causes and consequences 
of their elevation.
METHODS
The data, analytic methods, and study materials will be made 
available to other researchers for purposes of reproducing 
the results or replicating the procedure subject to a success-
ful project application to the Generation Scotland Access 
Committee, and requisite associated ethical approval for 
access to linked health data from NHS Scotland.
Study Recruitment
The recruitment and design of GS:SFHS has been reported else-
where.9,10 During 2006 to 2010, potential participants (aged 
35–65 years) were identified and invited at random from col-
laborating general medical practices in Scotland. Participants 
were asked to identify ≥1 first-degree relatives aged ≥18 
years who would also be able to participate. Subsequently, 
21 476 participants aged between 18 and 98 years attended 
a staffed research clinic in Scotland. Participants completed 
a health questionnaire, and had physical and clinical char-
acteristics measured according to a standardized protocol.10 
Past medical history, including a diagnosis of diabetes mellitus 
(type 1 or type 2) and CVD (previous myocardial infarction or 
stroke), and use of medications was self-reported. Family his-
tory of CVD was defined as a self-report of parents or siblings 
having heart disease or stroke. Fasting blood samples were 
taken, according to a standard operating procedure, and 
serum samples were separated. Baseline biochemistry includ-
ing total cholesterol, high-density lipoprotein cholesterol, and 
serum creatinine, were measured at the time of collection, 
and additional serum aliquots were stored at –80°C for future 
biochemical analyses. Scottish Index of Multiple Deprivation 
scores, nationally compiled composite measures of small-area 
deprivation, were derived from participant postcodes.11 The 
study obtained written informed consent from all partici-
pants and received ethical approval from the National Health 
Service Tayside Committee on Medical Research Ethics (REC 
Reference Number: 05/S1401/89).
Measurement of High-Sensitivity 
Troponins
High-sensitivity cTnT (Roche Diagnostics) and high-sensi-
tivity cTnI (ARCHITECT STAT, Abbott Laboratories, Abbott 
Clinical Perspective
What Is New?
• High-sensitivity cardiac troponin I and troponin T 
have different associations with health outcomes, 
including specific cardiovascular disease outcomes, 
in the general population.
• Upstream genetic causes of elevated cardiac tropo-
nin I and troponin T in healthy people also appear 
distinct from each other.
What Are the Clinical Implications?
• Cardiac troponin I appears to be a more specific 
marker of risk of composite cardiovascular disease 
and coronary heart disease, whereas cardiac tropo-
nin T is more strongly associated with risk of non–
cardiovascular disease death.
• Both cardiac troponin I and cardiac troponin T were 
associated with heart failure and cardiovascular dis-
ease death.
• These findings help inform the selection of an 
optimal troponin assay for future clinical care and 
research in the general population.
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Diagnostics) were measured on Cobas e411 and i1000SR 
analyzers, respectively, using the manufacturers’ calibrators 
and quality controls.6 We also participated in the UK National 
External Quality Assurance Scheme for these biomarkers dur-
ing the conduct of study. The limit of blank of the cTnT assay 
is set to 3 ng/L by the manufacturer, whereas we reported 
anything <1.2ng/L for cTnI as below the limit of blank.12 
Results below the limit of blank (undetectable) are reported 
as half of the limit of blank (ie, 1.5 ng/L for cTnT and 0.6 ng/L 
for cTnI) for continuous analyses. A total of 19 501 individuals 
provided measurements of both troponins.
Health Outcomes
Participants were followed to the end of September 2017 for 
deaths or hospitalizations for events of interest. Outcomes 
were identified by using a national database: the Information 
Services Division National Health Service record linkage for 
Scotland. This contains information on Scotland’s morbidity 
records for acute specialty day case and inpatient discharges 
from hospital (Scotland’s morbidity record 01) since January 
1981. Causes of death, derived from death certificates, were 
obtained from National Health Service Central. For this study, 
the primary composite CVD outcome was any event included 
in the national ASSIGN risk score definition of CVD,13 includ-
ing any International Classification of Diseases, 10th Revision 
codes I20–25, G45, I60–69, and death from CVD (I00–I99), as 
well, and OPCS-4 (Office of Population Censuses and Surveys: 
Classification of Interventions and Procedures version 4) pro-
cedure codes L29.5, L31.1, K40–46, K49, and K75 (proce-
dures comprising carotid endarterectomy, carotid angioplasty, 
coronary artery bypass graft, and percutaneous transluminal 
coronary angioplasty). CVD death included deaths coded 
from underlying causes I00 to I99; all others were classified as 
non-CVD deaths. Other clinical outcomes (fatal or nonfatal) 
included coronary heart disease (I00–I25), myocardial infarc-
tion (I21, I22), ischemic stroke (I63, I64, G45), any malignancy 
(C00–C97), and hospitalization for heart failure (I50, I42.0, 
I42.6, I42.7, I42.9, I11.0).
Genome-Wide Association Study
Details on blood collection and DNA extraction are provided 
elsewhere.14 Samples were genotyped using the Illumina 
Human OmniExpressExome-8v1.0 Bead Chip and Infinum 
chemistry and processed using the Illumina Genome Studio 
Analysis software v2011 (Illumina). Quality control was per-
formed to remove single-nucleotide polymorphisms (SNPs) 
with <98% call rate, individuals with a genotyping rate <98%, 
and SNPs with a Hardy Weinberg equilibrium test P value of 
≤1×10−6 and a minor allele count of <50. Individuals who were 
identified as population outliers through principal component 
analyses of their genotypic information were also removed.15 
Following quality control there were 19 904 GS:SFHS individuals 
(11 731 women and 8173 men) that had genotypic information 
for 561 125 autosomal SNPs, with 19 130 participants having 
phenotyping for at least one troponin. To increase the density 
of variants throughout the genome, the genotyped data were 
imputed using the Sanger Imputation Service (https://imputa-
tion.sanger.ac.uk/) using the Haplotype Reference Consortium 
panel v1.1.16 Autosomal haplotypes were checked to ensure con-
sistency with the reference panel (strand orientation, reference 
allele, position) then prephased using Shapeit2 v2r837,17,18 the 
Shapeit2 duohmm option11,19 taking advantage of the cohort 
family structure to improve the imputation quality. Monogenic 
and low imputation quality (info score < 0.4) variants were 
removed from the imputed data set leaving 24 111 857 variants 
available for downstream analysis.
Statistical Analysis for Risk Associations
The intraclass correlation coefficients for cTnT and cTnI were 
0.18 (95% CI, 0.16–0.19) and 0.09 (95% CI, 0.07–0.10), 
respectively, for clustering within family groups. Allowing for 
familial clustering had no appreciable effect on any analy-
ses, so the results presented here are from analyses without 
adjustment for clustering. Multiple imputation by chained 
equations was used to account for missing data for classi-
cal risk factors (but not missing troponin concentrations) in 
regression models. Ten imputed data sets were used.
To illustrate associations of troponins and classical risk fac-
tors with health outcomes, available complete data were pre-
sented using categorical variables expressed as frequencies 
and percentages, and continuous variables were presented 
as medians (interquartile interval) or mean (SD). Each tro-
ponin was split into 3 unequal groups (low: cTnT <3.0 ng/L 
and cTnI ≤1.8 ng/L; intermediate: cTnT 3.0–5.7 ng/L and cTnI 
1.9–3.0ng/L; high: cTnT ≥5.8 ng/L and cTnI ≥3.1 ng/L), so that 
the proportion within each grouping was similar for each tro-
ponin. Kaplan–Meier curves were used to illustrate the asso-
ciation of the 3 groups of each troponin with incident CVD.
Unadjusted and adjusted (for age, sex, total cholesterol, 
high-density lipoprotein cholesterol, systolic blood pressure, 
number of cigarettes smoked per day, rheumatoid arthri-
tis, diabetes mellitus, Scottish Index of Multiple Deprivation 
score, family history of CVD, cholesterol-lowering medication, 
blood pressure–lowering medication, and baseline CVD). Cox 
proportional hazards models were used to investigate the 
association of the troponins with health outcomes. Further 
adjustment for body mass index and creatinine made no 
substantial difference (data not shown). The shapes of the 
associations were tested and illustrated using restricted cubic 
splines (knots at 2, 3, 5, 10, and 25 pg/mL for cTnI, and at 
3.3, 5, 8, 10, and 25 pg/mL for cTnT) and also modeled using 
troponins as continuous risk factors (per 1 SD increase after 
log-transformation). The proportional hazards assumption 
was tested by plotting Schoenfeld residuals. Tests for interac-
tion of cTnT and cTnI with CVD events were also conducted 
by baseline classical risk factors. The 95% CI for the differ-
ence in the log hazard ratio for cTnI and cTnT was obtained by 
bootstrapping (5000 times); exponentiation of the difference 
in the log hazard ratios gives the ratio of the hazard ratios. 
Improvement in the clinical prediction of primary CVD (using 
age, sex, total cholesterol, high-density lipoprotein choles-
terol, systolic blood pressure, number of cigarettes per day, 
Scottish Index of Multiple Deprivation score, diabetes mellitus, 
family history of CVD, and rheumatoid arthritis) on the addi-
tion of each troponin individually was tested (in participants 
without baseline CVD and aged ≥40 years) using the continu-
ous net reclassification index and integrated discrimination 
index. These tests were conducted using the nricens pack-
age (R) with 5000 bootstraps. All analyses were performed in 
STATA (version 14.2) and R (version 3.3.1).
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Statistical Analysis for GWAS
GS:SFHS has previously been used in a variety of GWAS stud-
ies and the imputed data are research ready.20,21 There were 
19 130 individuals with a troponin result and quality-con-
trolled genomic data.
Genome-wide associations were performed on Haplotype 
Reference Consortium–imputed data, only results from vari-
ants with a minor allele count of 50 in our sample. For 
each phenotype, an additive model for the fitted SNP fixed 
effect was set up incorporating age and sex as covariates 
and a random polygenic effect accounting for the related-
ness among participants. Phenotypes were inverse-normal 
transformed to ensure a normal distribution of the model’s 
residuals, using the rntransform function in the GenABEL 
R package.22 Associations with the Haplotype Reference 
Consortium–imputed variants were performed with the 
software RegScan v0.2.23 The pgresidualY estimated from 
the polygenic function in GenABEL was used for association 
analysis. The effect size, standard errors, and P values were 
thereafter corrected to account for relatedness using the 
GRAMMAR-Gamma factors also provided by the polygenic 
function.24 The polygenic command in the GenABEL R pack-
age was used to calculate Genetic kinship-based heritability. 
The standard errors of heritability estimates were obtained 
by rerunning the polygenic command and fixing the herita-
bility to 0.
GWAS significance of SNPs is attained at a P value of 
<5×10–8, and suggestive hits at P value <1×10–5. Manhattan 
plots are used to illustrate hits using these thresholds. All 
suggestive hits for both troponins were read into FUMA25 
(https://fuma.ctglab.nl) to identify loci of interest and func-
tional annotations. The 1000-genome European reference 
panel (phase 3) was used to account for linkage disequilib-
rium in the sample. For the primary analyses, we focused only 
on SNPs that attained a GWAS significant association, with a 
further sensitivity analysis using a more relaxed criterion for 
exploration; the minimum value of a lead SNP was taken at 
a P value of <5×10–7, and without a minimum minor allele 
frequency, to maximize loci identification. However, interpre-
tation of results in this sensitivity analysis should place less 
emphasis on rare isolated variants
RESULTS
Crude Associations of Troponins With 
Classical Risk Factors and With CVD
Detectable concentrations of cTnI and cTnT were 
found in 14 579 participants (74.8%) and 10 395 par-
ticipants (53.3%), respectively. Both troponins were 
generally associated with adverse classical CVD risk 
factors, with the exception that cTnI and cTnT were 
inversely associated with current smoking, and cTnT 
was inversely associated with total cholesterol (Table 
I in the online-only Data Supplement). The Spearman 
correlation coefficient between cTnT and cTnI was 
r=0.443 (P<0.001).
Median follow-up was 7.8 years (quartile 1 to quar-
tile 3, 7.1–9.2) for the primary composite CVD end 
point. Of the 19 501 participants, 1177 experienced 
an incident CVD during follow-up (6.0%), 640 par-
ticipants died (3.3%), and 266 died of CVD causes 
(1.4%). Participants who experienced the composite 
CVD outcome, in general, had a more adverse risk 
factor profile, including being older, more frequently 
being male, having a higher body mass index, higher 
blood pressure, lower high-density lipoprotein choles-
terol (but also a lower total cholesterol), and a higher 
deprivation score; they were more frequently smok-
ers, and were more likely to have baseline CVD, dia-
betes mellitus, or rheumatoid arthritis, or to be taking 
cholesterol- or blood pressure–lowering medication 
(Table  1). Those who experienced a composite CVD 
event had almost a 2-fold higher median baseline cTnI 
and cTnT (Table 1). Similar results were found for oth-
er outcomes of interest; both troponins were higher 
in those who experienced every adverse outcome of 
interest (Tables II through IX in the online-only Data 
Supplement). Kaplan–Meier curves show that both 
cTnI and cTnT were associated with the probability of 
CVD-free survival (both log rank tests P<0.001; Figure 
I in the online-only Data Supplement).
Table 1. Association of Classical Risk Factors and Troponin I and 
Troponin T With Composite CVD Events
Risk Factors
No Incident 
CVD
n=18 324
Incident CVD
n=1177 P Value
Age, y 46.1±14.61 62.5±11.6 <0.0001
Male sex, n (%) 7443 (40.6) 683 (58.0) <0.0001
BMI, kg/m2 26.6±5.2 28.4±5.1 <0.0001
SBP, mm Hg 130.7±17.5 140.7±20.2 <0.0001
Total cholesterol, mmol/L 5.11±1.07 5.00±1.20 0.0013
HDL cholesterol, mmol/L 1.47±0.41 1.34±0.41 <0.0001
SIMD, score/10 1.69±1.44 1.96±1.67 <0.0001
Creatinine 73.3±15.3 81.6±22.3 <0.0001
Cigarettes per day 2.35±6.75 4.05±9.88 <0.0001
Current smoking 2829 (16.0) 227 (20.0) 0.0003
Family history of CVD 6953 (38.8) 451 (38.9) 0.9095
Rheumatoid arthritis 262 (1.4) 52 (4.4) <0.0001
Baseline CVD 507 (2.8) 370 (31.4) <0.0001
Baseline diabetes mellitus 429 (2.3) 133 (11.3) <0.0001
Cholesterol medications 998 (5.4) 284 (24.1) <0.0001
Blood pressure medication 1276 (7.0) 298 (25.3) <0.0001
cTnT, ng/L 3.2 [1.5–5.8] 6.2 [3.2–10.7] <0.0001
cTnI, ng/L 1.8 [0.6–3.0] 3.3 [0.6–5.9] <0.0001
P values are from independent sample t tests for continuous variables with 
normal distribution (ie, mean±SD), Mann–Whitney U test for continuous 
variables with skewed distribution (ie, median [quartile 1 to quartile 3], or χ2 
test for categorical variables (ie, n [%]). BMI indicates body mass index; cTnI, 
high-sensitivity troponin I; cTnT, high-sensitivity troponin T; CVD, cardiovascular 
disease; HDL, high-density lipoprotein; SBP, systolic blood pressure; and SIMD, 
Scottish Index of Multiple Deprivation.
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Shape of the Association of Troponins 
With Outcomes
Using undetectable levels of each troponin as the refer-
ent, the association of elevated troponin with composite 
CVD was explored by restricted cubic splines (Figure 1). 
For both cTnI and cTnT, there was a rapid rise in risk 
in unadjusted models. For instance, at a cTnI level of 5 
ng/L, the hazard ratio (HR) was 7.7 (95% CI, 6.3–9.3) in 
comparison to undetectable cTnI, and at 20ng/L, the HR 
was 12.8 (9.9–16.5). The corresponding HRs for cTnT 
were 2.2 (1.9–2.7) and 12.2 (10.1–14.9), respectively. 
For both troponins, there was a leveling off in increasing 
risk at higher levels of troponin. Adjustment for clas-
sical risk factors attenuated the associations for both 
troponins substantially, and made the associations more 
linear. In the adjusted model, at values of 5 ng/mL and 
20 ng/L, the HRs were 1.5 (1.2–1.9) and 2.6 (1.9–3.4) 
for cTnI, and 0.97 (0.80–1.17) and 1.4 (1.1–1.8) for 
cTnT, respectively. The associations of both troponins 
with CVD death were more pronounced (Figure II in 
the online-only Data Supplement). Only cTnT showed 
trends toward a positive relationship with non-CVD 
death in adjusted models (Figure III in the online-only 
Data Supplement) and therefore had stronger associa-
tions with all-cause mortality (Figure IV in the online-
only Data Supplement). Only cTnI, not cTnT, was associ-
ated with myocardial infarction (MI) and coronary heart 
disease (CHD; Figures V and VI in the online-only Data 
Supplement), and adjustment for age and sex alone was 
sufficient to ameliorate the association between cTnT 
and MI or CHD (data not shown). Both cTnI and cTnT 
were associated with ischemic stroke and heart failure 
(Figures VII and VIII in the online-only Data Supplement). 
After adjustment, neither troponin was associated with 
cancer (Figure IX in the online-only Data Supplement).
A higher category (low/intermediate/high) of cTnI was 
associated with increased unadjusted rate of composite 
CVD within each category of cTnT (Figure 2). Likewise, a 
higher category of cTnT was associated with increased 
rate of composite CVD within each category of cTnI (Fig-
ure 2). After controlling for cTnT, each category increase 
Figure 1. Association of cTnI and cTnT unadjusted and adjusted (as per Table 2) with the composite CVD event. 
The referent (HR=1) is undetectable levels of cTnI and cTnT, respectively. Both splines on log scale. cTnI indicates high-sensitivity cardiac troponin I; cTnT, high-
sensitivity cardiac troponin T; CVD, cardiovascular disease; and HR, hazard ratio.
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in cTnI had a HR of 1.92 (95% CI, 1.77–2.07) for com-
posite CVD in comparison with the preceding category. 
After controlling for cTnI, the HR for one category in-
crease in cTnT was 1.64 (95% CI, 1.52–1.78).
Comparison of the Association of cTnI 
and cTnT With Outcomes
We then compared the extent of the adjusted associa-
tion of cTnI and cTnT with the different outcomes. One 
standard deviation increase in log cTnI was associated 
with a HR of 1.24 for composite CVD, whereas the HR 
was 1.11 for 1 SD increase in log cTnT. The ratio of 
these HRs indicates that the association with composite 
CVD was stronger for cTnI: 1.12 (95% CI, 1.04–1.21; 
Table  2). Both troponins had similarly strong associa-
tions with CVD death, and both had stronger asso-
ciations with CVD death than for the composite CVD 
outcome (Table 2). Both troponins were also strongly 
associated with heart failure (Table  2). cTnT, but not 
cTnI, had an association with non-CVD death (ratio of 
HRs, 0.77; 95% CI, 0.67–0.88), and consequently cTnT 
also had a stronger association with all-cause death 
than cTnI (Table 2). In contrast, only cTnI was associ-
ated with MI or CHD; cTnT showed no association with 
either outcome. Both troponins showed an associa-
tion with ischemic stroke, and neither was associated 
with incident cancer after adjustment (Table 2). When 
both cTnI and cTnT were included in the same adjusted 
model together, only cTnI remained associated with the 
composite CVD outcome (Table 3).
Interaction by Classical Risk Factors
Investigating interactions by baseline risk factors for the 
composite CVD outcome, both cTnI and cTnT showed 
trends to be less strongly associated with composite 
CVD among those with baseline CVD or taking blood 
pressure– or cholesterol-lowering medications (Figure 
X in the online-only Data Supplement). cTnI was more 
strongly associated with composite CVD risk among pa-
tients with diabetes mellitus (P for interaction 0.009; 
Figure X in the online-only Data Supplement). There 
were no other notable interactions.
Figure 2. Rates of CVD per 1000 person-
years (n=1177 events) by low/intermedi-
ate/high groupings of both cTnI and cTnT.  
For cTnI: low ≤1.8ng/L (n=9426), intermediate 
1.9 to 3.0 ng/L (n=5052), and high ≥3.1 ng/L 
(n=5023). For cTnT: low ≤3.0 ng/L (n=9106), 
intermediate 3.0 to 5.7 ng/L (n=5200), and 
high ≥5.8 ng/L (n=5195). cTnI indicates high-
sensitivity cardiac troponin I; cTnT, high-sensitiv-
ity cardiac troponin T; and CVD, cardiovascular 
disease.
Table 2. Association of Troponin I and Troponin T (per 1 SD Increase 
on the Log Scale) With Risk of Different Events, Adjusted for Classical 
Risk Factors, and the Troponins in Separate Models
CVD Events
Troponin I Troponin T
Ratio of the 
Hazard Ratio* 
(95% CI)
Hazard Ratio 
(95% CI)
Hazard Ratio 
(95% CI)
CVD (n=1177) 1.24 
(1.17–1.32)
1.11 
(1.04–1.19)
1.12 
(1.04–1.12)
CVD death (n=266) 1.56 
(1.38–1.75)
1.52 
(1.31–1.77)
1.02 
(0.87–1.20)
Non-CVD death (n=374) 1.04 
(0.92–1.17)
1.35 
(1.20–1.52)
0.77 
(0.67–0.88)
All-cause death (n=640) 1.25 
(1.15–1.36)
1.42 
(1.29–1.55)
0.88 
(0.80–0.98)
MI (n=259) 1.18 
(1.04–1.35)
0.93 
(0.81–1.08)
1.27 
(1.07–1.48)
CHD (n=812) 1.19 
(1.11–1.28)
1.04 
(0.96–1.13)
1.14 
(1.04–1.25)
Ischemic stroke (n=205) 1.39 
(1.21–1.60)
1.22 
(1.04–1.43)
1.15 
(0.97–1.36)
Heart failure (n=216) 1.86 
(1.66–2.08)
1.69 
(1.43–1.98)
1.10 
(0.93–1.31)
Cancer (n=1078) 0.96 
(0.90–1.04)
1.00 
(0.93–1.07)
0.96 
(0.89–1.04)
Model adjusted for age, sex, total cholesterol, high-density lipoprotein 
cholesterol, systolic blood pressure, cigarettes smoked per day, rheumatoid 
arthritis, diabetes mellitus, Scottish Index of Multiple Deprivation score, 
family history of CVD, use of blood pressure medications, and use of 
cholesterol-lowering medications. CHD indicates coronary heart disease; CVD, 
cardiovascular disease; and MI, myocardial infarction.
*Troponin I:troponin T ratio.
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Primary Composite CVD Prediction 
Models
Using the continuous net reclassification index, a clini-
cal prediction model in those without baseline CVD 
and aged ≥40 years (n=12 496) was improved by the 
addition of cTnI which yielded a continuous net re-
classification index improvement of 7.7% (95% CI, 
2.8%–11.7%; P=0.004), and an integrated discrimina-
tion index of +0.005 (95% CI, 0.002–0.009; P<0.001). 
The clinical prediction model also showed a trend to 
be improved by addition of cTnT separately, yielding a 
continuous net reclassification index improvement of 
8.0% (95% CI, –2.3% to 11.9%; P=0.064), and an 
integrated discrimination index of +0.001 (95% CI, 
0.000–0.002; P=0.001).
GWAS for cTnI and cTnT
Heritability of cTnI was 0.249±0.013 and cTnT was 
0.35±0.011. There were 5 loci for cTnI that reached 
genome-wide significance (Figure 3A). These included 
SNPs at KLKB1 (4q35.2: 23 SNPs at GWAS significance), 
VCL/AP3M1/ADK (10q22.2: 2 SNPs), ANO5 (11p14.3: 
14 SNPs), CEP95/SMURF2 (17q23.3: 3 SNPs), and 
LMAN1/CPLX4 (18q21.32: 11 SNPs) genes (Table  4). 
There was an isolated intergenic SNP in chromosome 
1 that was of borderline genome-wide significance, 
flanking a suggestive hit for DAB1 (1p32.1) SNP. There 
were marked differences in the GWAS Manhattan plot 
for cTnT in comparison to cTnI (Figure 3B), with limited 
overlap of associated loci, and far fewer suggestive loci 
associated with cTnT in general. There were isolated 
low-frequency SNPs at the genes of C1orf112, TRA-
BD2A (2p11.2), SORBS2 (4q35.1), and PTPRD (9p23) 
for cTnT (Table 4).
Using a more relaxed threshold for statistical signifi-
cance identified other loci of potential interest. For cTnI, 
a locus at F12/GRK6 (5q35.3: 5 SNPs) also showed sug-
gestive trends toward association (Table X in the on-
line-only Data Supplement). For cTnT, there was also 
a suggestive hit for a locus at POC1B (12q21.33: 16 
SNPs) and TMEM131/ZAP70 (2q11.1: 4 SNPs). Exclud-
ing those with baseline CVD had minimal impact on the 
primary genetic associations (Table XI in the online-only 
Data Supplement).
DISCUSSION
This study highlights several important findings that 
are relevant to potential future clinical use of high-
sensitivity troponins in CVD risk prediction, and also 
relevant to scientific enquiries into the etiology of 
elevated troponin in apparently healthy people. It is 
most remarkable that we demonstrate the striking 
differences in cTnI and cTnT in terms of their asso-
ciation with composite CVD and with specific CVD 
outcomes. Both have similar strong associations with 
risk of CVD death and heart failure, and both have as-
sociations with ischemic stroke. It is most surprising, 
however, that cTnT showed no association with MI or 
CHD after adjusting for classical risk factors; cTnI did. 
As a result, cTnI was more strongly associated with 
the primary composite CVD outcome. In fact, cTnT 
showed an association with non-CVD death but cTnI 
did not. These findings suggest different upstream 
causes of modest elevations in cTnI and cTnT in the 
general population. In line with this, our GWAS high-
lights little overlap in the genetic determinants of cir-
culating cTnI and cTnT. This is in line with our previous 
report, demonstrating differences in the associations 
of classical risk factors with the troponins in a cross-
sectional study.6
In a recent study level meta-analysis,4 in the top ver-
sus bottom third of the population for each troponin, 
the HR of CVD was nominally stronger for cTnT than 
cTnI (HR=1.60 versus 1.36; P=0.171), and cTnT was 
more strongly associated with fatal CVD (P=0.027). 
However, the troponins were measured in different 
cohorts, which limits the ability to make direct com-
parisons. Our study is the first large general population 
study of which we are aware to compare systematically 
the disease associations of the 2 troponins directly.
The lack of association of cTnT with MI and CHD, 
after adjusting for classical risk factors, is unexpected, 
given that the source of both troponins is cardiac in-
jury. Indeed, previous studies demonstrate that cTnT 
is associated with left ventricular hypertrophy26 and 
coronary plaque count, and plaque phenotype, as 
well.27,28 The MI and CHD outcomes were  associated 
Table 3. Association of Troponin I and Troponin T (per 1 SD Increase 
on the Log Scale) With Risk of Different Events, Adjusted, With Both 
Troponins in the Same Model
CVD Events 
Troponin I Troponin T
Hazard Ratio
(95% CI)
Hazard Ratio
(95% CI)
CVD (n=1177) 1.23 (1.15–1.32) 1.02 (0.94–1.09)
CVD death (n=266) 1.42 (1.24–1.63) 1.27 (1.07–1.50)
Non-CVD death (n=374) 0.92 (0.81–1.05) 1.39 (1.22–1.57)
All cause death (n=640) 1.12 (1.02–1.23) 1.35 (1.22–1.49)
MI (n=259) 1.26 (1.09–1.45) 0.85 (0.73 – 0.99)
CHD (n=812) 1.21 (1.12–1.31) 0.96 (0.88–1.05)
Ischemic stroke (n=205) 1.36 (1.17–1.59) 1.07 (0.90–1.27)
Heart failure (n=216) 1.72 (1.51–1.95) 1.25 (1.04–1.49)
Cancer (n=1078) 0.96 (0.89–1.04) 1.01 (0.94–1.09)
Model adjusted for age, sex, total cholesterol, high-density lipoprotein 
cholesterol, systolic blood pressure, cigarettes smoked per day, rheumatoid 
arthritis, diabetes mellitus, Scottish Index of Multiple Deprivation score, family 
history of CVD, use of blood pressure medications, use of cholesterol-lowering 
medications, and each troponin adjusted for the other. CHD indicates coronary 
heart disease; CVD, cardiovascular disease; and MI, myocardial infarction.
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with cTnT in unadjusted models, and with cTnI in 
adjusted models, so the lack of association is not ex-
plained by outcome misspecification. Given the addi-
tional association of cTnT with fatal non-CVD events, 
it is interesting to speculate what causes cTnT eleva-
tion beyond classical risk factors in apparently healthy 
people. cTnT is known to be transiently expressed in 
fetal skeletal muscle,29 and it may be possible that 
noncardiac tissues express cTnT in some circumstanc-
es. For instance, patients with neuromuscular diseases 
but with no evidence of heart disease may have el-
evated cTnT, but not an elevated cTnI.30–32 cTnT is also 
known to be a strong predictor of adverse noncardiac 
outcome following abdominal surgery.33 As such, dif-
ferent etiological causes of elevations in cTnI and cTnT, 
and consequently different downstream risks, may be 
sufficient to explain our findings.
Upstream genetic determinants of the troponins also 
appear distinct. For cTnI, the KLKB1 and F12 genes are 
both part of the kallikrein-kinin axis and loci have been 
associated with biomarkers of endothelin-1, proadreno-
medullin,34 B-type natriuretic peptide,35 and l-arginine, 
as well.36 Given this broad association with vasoactive 
peptides, it is interesting that the loci are associated 
with cTnI, but no association is seen for cTnT. Plasma 
prokallikrein is activated by active factor XII (encoded by 
F12) and colocalizes to endothelial cells. Activated kal-
likrein is also involved in procession vasoactive peptides 
such as bradykinin and renin.37 The loci around VCL 
encode vinculin membrane–associated protein, which 
is perhaps particularly relevant to troponin expression, 
because it appears involved in cytoskeletal modeling in 
diseased cardiac tissue.38,39 The anoctamin-5 protein en-
coded by ANO5 is a poorly characterized chloride chan-
nel found in skeletal and cardiac muscle, and mutations 
may be associated with cardiomyopathy.40 Allelic vari-
ants of LMAN1 gene are associated with factor V-factor 
VIII deficiency.41 In contrast, genes associated with cTnT 
include ArgBP2 (SORBS2), which is highly abundant in 
cardiac z-disc structures.42 There is hence a strong bio-
logical background for many of these genes being as-
sociated with cardiac injury or troponin leakage.
Strengths of the study include the use of a large and 
well-phenotyped prospective nationwide  population 
Figure 3. Manhattan plots for single-nucleotide polymorphisms associated with cTnI and cTnT after adjustment for age and sex (n=19 130).   
A, cTnI. B, cTnT. The horizontal black dotted line indicates genome-wide significance at P<5×10–8, and the horizontal gray dotted line suggests significance at 
P<1×10–5.
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study of broadly healthy people, where national re-
cord linkage has been used for follow-up. Numbers 
of outcomes lend the study considerable statisti-
cal power. The direct comparisons of cTnI and cTnT 
in terms of risk associations in a general population 
is novel, and is supported by the GWAS in a cohort 
with an established approach to such studies. Weak-
nesses include the family structure of the study, al-
though sensitivity analyses suggest family clustering 
had very limited impact on data in terms of clustering 
within families. The study population is not ethnically 
diverse, limiting generalizability in that regard, but in-
cludes a wide age range from participants of both sex-
es. In common with many electronic health records, 
the small proportion of the population who emigrate 
from Scotland43 will not have recorded outcomes of 
interest, but might still be considered at risk in our 
models. This may slightly bias estimates, but is unlikely 
to affect the direct comparison between biomarkers. 
A large proportion of participants had undetectable 
troponin. This is suboptimal for continuous statistical 
analyses, but we demonstrate results using a number 
of different models. We also acknowledge that, in in-
dividual patients, as opposed to population studies, 
accurate measurement of low troponin levels would 
be important in using troponin levels to determine 
clinical risk. Our observations offer limited causal in-
sight as to the reasons underlying differential associa-
tions of cTnI and cTnT with different outcomes. How-
ever, etiological differences in the upstream causes of 
different troponin elevations are supported by GWAS, 
and, as such, our data are sufficient to indicate that 
care should be taken when selecting a high-sensitivity 
troponin to use as a biomarker in general population 
studies, or as surrogate biomarkers in trials, depend-
ing on the aims of the study.
In conclusion, we demonstrate that routine clini-
cal cTnI and cTnT assays have different associations 
with composite cardiovascular and non-CVD mortal-
ity outcomes in apparently healthy people; the cTnI 
assay is specific for CVD risk, whereas the cTnT assay 
is more strongly associated with non-CVD mortality. 
Table 4. Lead SNPs, and Other SNPs in the Same Loci, With Genome-Wide Association Study Significant Associations With Either Troponin (at 
P<5×10–8)
Lead SNP Chromosome Position
Noneffect 
Allele
Effect 
Allele
Minor 
Allele 
Frequency P Value β Other SNPs Nearest Gene
Troponin I (n=19 130)
rs4253248 4 187155488 G A 0.4871 1.25×10–08 0.050 rs12331618; rs11132382; 
rs4862669; rs2048; 
rs4253238; rs1912826; 
rs3775298; rs1511801; 
rs4241815; rs4241816; 
rs4241817; rs4241818; 
rs4253252; rs3733402; 
rs4253254; rs4253255; 
rs66530140; rs35984397; 
rs4253281; rs4253282; 
rs1973612; rs4253311
KLKB1, CYP4V2, 
F11
rs71483973 10 75900464 A G 0.1679 2.80×10–09 0.072 rs11817132 VCL,AP3M1,ADK
rs7481951 11 22271870 A T 0.4107 5.77×10–10 0.055 rs12790951; rs4635079; 
rs4244488; rs4244490; 
rs12807778; rs12290197; 
rs4275631; rs4478991; 
rs10833711; rs10833712; 
rs4408310; rs10741930; 
rs10833719
ANO5
rs148050755 17 62516959 A C 0.0026 3.28×10–11 –0.774 rs187364357; rs138838734 CEP95,SMURF2
rs2298711 18 57000469 T A 0.1512 9.80×10–12 0.083 rs117153087; rs12604758; 
rs41468947; rs17696641; 
rs12604424; rs12608430; 
rs149168942; rs77905572; 
rs4940867; rs78723480
CPLX4,LMAN1
Troponin T (n=19 127)
rs16862512 1 169649691 T C 0.0050 3.34×10–08 0.349  C1orf112
rs548487604 2 85111553 G C 0.0014 9.29×10–09 0.749  TRABD2A
rs75898208 4 186911043 G A 0.0017 1.69×10–09 0.735  SORBS2
rs184140292 9 8457116 T C 0.0017 9.84×10–09 0.706  PTPRD
SNP indicates single nucleotide polymorphism.
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It also  appears that their genetic determinants are 
largely distinct. Future research studies should use this 
evidence base to select a troponin for cohort pheno-
typing depending on the study aims. This information 
is also of relevance to attempts to improve CVD risk 
stratification in the population by using cardiac tropo-
nin measurements.
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